Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women

Climacteric

Volumn 11, Issue 5, 2008, Pages 390-396

  Dias Jr , A R ^a   De Mello, N R ^a   Eluf Gebara, O C ^a   Nussbacher, A ^a   Wajngarten, M ^a   Petti, D A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial stiffness; Cardiovascular disease; Hormone replacement therapy; Postmenopause; Raloxifene therapeutic use; Vascular compliance

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FEMORAL ARTERY; HEART RATE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TONOMETRY;

ADULT; AGED; ARTERIES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HEART RATE; HUMANS; MANOMETRY; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; ULTRASONOGRAPHY, DOPPLER;

EID: 51649127014     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802325635     Document Type: Article

References (25)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
2. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67
4. Dias AR Jr, Melo NR, Gebara OCE, et al. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 2005;8:63-70
5. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and the metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
6. Gebara OCE, Mittleman MA, Walsh BW, Lipinska I, Bellotti G. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998;80:235-9
7. Nussbacher A, Gerstenblith G, O'Connor FC, et al. Hemodynamic effects of unloading the old heart. Am J Physiol 1999;277:H1863-71
8. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41
9. O'Rourke MF, Hayward CS. Arterial stiffness, gender and heart rate. J Hypertens 2003;21:487-90
10. Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter E. Mortality associated with hormone replacement therapy in younger and older women - a meta-analysis. J Gen Intern Med 2004;19:791-804
11. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. II. Circulation 2003;107:346-54
12. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983;68:50-8
13. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989;80:1652-9
14. Zar JH. Biostatistical Analysis, 3rd edn. New York: Prentice Hall, 1996
15. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11
16. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxid release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-9
17. Wiernicki T, Glasebrook A, Singh JP. Estrogen and novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell function: implications in the cardio-protective mechanism of estrogen. Circulation 1996;94(Suppl I):1278
18. Sztejnsznajd C, Da Silva ME, Nussbacher A, et al. Estrogen treatment improves arterial distensibility, fibrinolysis and metabolic profile in postmenopausal women with type 2 diabetes mellitus. Metabolism 2006;55:953-9
19. Costa LS, de Oliveira MA, Rubim VS, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive post-menopausal women. Am J Cardiol 2004;94:1453-6
20. Rajkumar C, Kingwell BA, Cameron JD, et al. Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 1997;30:350-6
21. Hayward CS, Knight DC, Kelly RP. Effects of hormone replacement therapy on non-invasive cardiovascular haemodynamics. J Hypertens 1997;15:987-93
22. Jaszcz KK, Czarnecka D, Olszanecka A, Rajner M, Jankowski P. The effects of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002;16:509-16
23. Miura S, Tanaka E, Mori A, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003;45:293-8
24. Teede HJ, Liang YL, Kotsopoulos D, Zougas S, MacGrath BP. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 2001;55: 673-82
25. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in post-menopausal women with coronary artery disease. J Am Coll Cardiol 2003;42:698-704